Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the iShares U.S. Healthcare ETF (IYH), a passively managed exchange traded fund ...

National Signing Day for TSSAA football players is Wednesday, but college signees in other Tennessee high school sports have ...

Real-time index price for S&P 500 Communication Services [Sector] (SRTS), along with buy or sell indicators, analysis, charts ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.

Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...